BIOCELTIX S.A. ZY -10
Research BIOCELTIX S.A. ZY -10 (XI3) on Bullrun: market cap EUR 112.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXI3
- ExchangeF
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 112.86M
- Financial periodQ1 2026
- RevenuePLN 0
- Net income-PLN 5.68M
- Free cash flow-PLN 7.55M
Valuation Snapshot
latest market cap is EUR 112.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 0 | -PLN 15.30M | -PLN 13.92M | n/a | n/a | PLN 68.40M | PLN 314.90K | PLN 73.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 112.86M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BIOCELTIX S.A. ZY -10's market cap?
BIOCELTIX S.A. ZY -10's market capitalization is EUR 112.86M.
What does BIOCELTIX S.A. ZY -10 do?
Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project aimed at developing a cell-free biological drug to treat atopic dermatitis in dogs.